NeuroPace

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroPace reports robust Q4 performance and outlines growth strategies

NeuroPace's Q4 call highlighted strong performance, strategic priorities for 2023, and challenges in maintaining gross margins. The company's focus on revenue growth drivers, market recovery, and new center expansions positions it well for future growth.

NeuroPace reports record revenue in Q1 2023, raises full-year guidance

NeuroPace delivered strong revenue growth in Q1 2023, with a positive outlook for the full year. The company faces challenges in managing operating expenses and sustaining profitability. However, opportunities lie in product distribution, clinical trials, and strategic growth initiatives.

NeuroPace excels in Q2, raises revenue guidance amid strategic growth

NeuroPace's Q2 performance reflects strong growth momentum and improved financial health, supported by strategic partnerships and effective expense management. The company's focus on expanding patient access and optimizing sales operations positions it well for continued success in 2023.

NeuroPace reports robust Q3 earnings, eyes strategic growth opportunities

NeuroPace's Q3 performance reflects strong revenue growth, improved margins, and prudent cost management, positioning the company for sustained success.
While facing challenges in net losses and operating expenses, NeuroPace's operational achievements and financial stability provide a solid foundation for future growth.
By addressing cost structures, leveraging market opportunities, and adapting to evolving market dynamics, NeuroPace can enhance profitability and drive long-term value creation.

NeuroPace reports robust revenue growth and strategic collaborations for 2024

NeuroPace's strong performance in Q4 2023 and full-year results demonstrate growth momentum.
Strategic collaborations and a focus on cost management are key strengths.
Challenges include managing expenses and market dynamics, but growth opportunities are present.
Overall, NeuroPace is well-positioned for revenue growth and transformative impact in 2024.

NeuroPace reports strong Q1 revenue growth and strategic collaborations

NeuroPace's Q1 2024 performance reflects revenue growth, margin improvements, and strategic collaborations.
The company faces challenges in maintaining margins, financial discipline, and closing the treatment gap.
Opportunities lie in expanding therapy access, market growth, and executing the growth strategy.
Overall, NeuroPace is on track to drive revenue through product sales and strategic initiatives.

NeuroPace reports robust Q2 earnings, eyes growth through strategic initiatives

NeuroPace's Q2 2024 performance reflects revenue growth, improved gross margin, and strategic initiatives driving future expansion and market penetration.
While facing challenges in managing operating expenses and maintaining margins, the company's strong cash position and growth strategy present opportunities for sustained growth.
Overall, NeuroPace's focus on innovation, market expansion, and financial prudence positions it well for future success in the neurotechnology sector.

NeuroPace reports robust Q3 earnings, eyes growth in epilepsy market

NeuroPace's Q3 2024 performance reflects solid revenue growth, operational improvements, and strategic focus on innovation and market expansion.
While facing challenges such as operating losses and competitive pressures, the company is well-positioned to leverage growth opportunities in the epilepsy treatment market.
With a strong financial position, effective leadership enhancements, and proactive investor engagement, NeuroPace is poised for continued growth and market success.
Strategic initiatives and upcoming events underscore the company's commitment to driving value for stakeholders and advancing its position in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 10, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) --  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am Eastern Time.

NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference

NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended September 30, 2021.

NeuroPace Reports Third Quarter 2021 Financial Results

IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation  to treat primary generalized epilepsy in patients aged 12 and older

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021

MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors. Simultaneously, the company also announced the resignation of current board member, Evan Norton. Both changes are effective November 1, 2021.

NeuroPace Announces Addition of Lisa Andrade to the Board

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported that the company will be participating in three upcoming conferences.

NeuroPace to Participate in Upcoming Conferences

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended June 30, 2021.

NeuroPace Reports Second Quarter 2021 Financial Results

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (NASDAQ: NPCE), a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the broad launch of its nSight Platform, an online portal that helps physicians provide more personalized, data-driven epilepsy care by enabling them to remotely review patient progress, discover actionable insights, and track their clinic's overall patient outcomes. The RNS® System is the only FDA-approved ep

NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients' Seizure Burden

MOUNTAIN VIEW, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the second quarter of 2021 after market close on Thursday, August 12, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

NeuroPace To Report Second Quarter 2021 Financial Results on August 12, 2021

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.

Could This Recently IPOed Medical Device Maker Make You Rich?

Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy

NeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome

NeuroPace's (NPCE) CEO Mike Favet on Q1 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended March 31, 2021.

NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance

MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 before market open on Thursday, June 3, 2021. The company's management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time /8:00 a.m. Eastern Time.

NeuroPace To Report First Quarter 2021 Financial Results on June 3, 2021

MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the closing of its initial public offering of 6,900,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase 900,000 additional shares of common stock, at the initial public offering price of $17.00 per share. The gross proceeds to NeuroPace, before deducting underwriting discounts and commissions and offering expenses, were approximately $117.3 million. NeuroPace's common stock began trading on the Nasdaq Global Select Market on April 22, 2021 under the ticker symbol “NPCE.”

NeuroPace, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NeuroPace aims to improve the lives of epilepsy patients. The company has a savvy remote monitoring system which provides real-time action.

NeuroPace: Plenty Of Space To Grow

MOUNTAIN VIEW, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17.00 per share. All shares of common stock are being offered by NeuroPace for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and offering expenses. In addition, NeuroPace has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. NeuroPace's common stock is expected to begin trading on the Nasdaq Global Select Market on April 22, 2021, under the ticker symbol “NPCE”. The offering is expected to close on April 26, 2021, subject to the satisfaction of customary closing conditions.

NeuroPace, Inc. Announces Pricing of Initial Public Offering

UiPath

SkyWater Technology

Latham Group

Zymergen

There have been quite a few appealing Initial Public Offerings (IPOs) available on the market so far this year. Here are some upcoming IPOs that investors should be watching out for.

News for NeuroPace Stock (NPCE)